An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Rinvoq

Chemical Nameupadacitinib
Dosage FormExtended-release tablet (oral; 15 mg)
Drug ClassKinase inhibitors
SystemMusculoskeletal
CompanyAbbVie Inc.
Approval Year2019

Indication

  • Rinvoq is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Last updated on 2/1/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Rinvoq (upadacitinib) Prescribing Information 2019Abbvie
Document TitleYearSource
Upadacitinib for treating severe rheumatoid arthritis.2020NICE
Clinical review report: upadacitinib (rinvoq).2020CADTH
Pharmacoeconomic review report: upadacitinib (rinvoq).2020CADTH
Document TitleYearSource
Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. 2020Zeitschrift für Rheumatologie
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. 2019Immunotherapy
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. 2019Rheumatology (Oxford)
Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. 2019International Journal of Rheumatic Diseases
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. 2018Annals of Rheumatic Diseases
Document TitleYearSource
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. 2020Annals of the Rheumatic Diseases
Updated Greek Rheumatology Society guidelines for the management of rheumatoid arthritis. 2020Mediterranean Journal of Rheumatology